Evidence map›Paper›PMID 23798572›Full record

ArticleMolecular endocrinology (Baltimore, Md.)2013

Stimulation of proglucagon gene expression by human GPR119 in enteroendocrine L-cell line GLUTag.

Oleg G Chepurny, Daniela Bertinetti, Mandy Diskar, Colin A Leech, Parisa Afshari, Tamara Tsalkova, Xiaodong Cheng, Frank Schwede, Hans-G Genieser, Friedrich W Herberg and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular endocrinology (Baltimore, Md.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. GPharmacological reviews · 2021
    Review
  5. Article
  6. Article
  7. The Journal of biological chemistry · 2019
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Cyclic AMP sensor EPAC proteins and energy homeostasis.Trends in endocrinology and metabolism: TEM · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Oleg G ChepurnyDepartment of Medicine, State University of New York, Upstate Medical University, Syracuse, New York 13210, USA.
Daniela Bertinetti
Mandy Diskar
Colin A Leech
Parisa Afshari
Tamara Tsalkova
Xiaodong Cheng
Frank Schwede
Hans-G Genieser
Friedrich W Herberg
George G Holz
SUNY Upstate Medical University · USUniversity of Kassel · DEBiolog Life Science Institute · DEThe University of Texas Medical Branch at Galveston · US

Funding

Epac/cAMP-GEF, A Novel Intracellular cAMP ReceptorR01GM066170 · NIGMS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI CHENG, XIAODONG · 2003 to 2017
$4.6M
Molecular Basis of Antidiabetogenic Hormone ActionR01DK069575 · NIDDK · UPSTATE MEDICAL UNIVERSITY · PI HOLZ, GEORGE G · 2007 to 2017
$2.9M
NIDDK NIH HHS 5R01-DK069575NIDDK NIH HHS R01 DK069575NIGMS NIH HHS 5R01-GM066170NIGMS NIH HHS R01 GM066170
6 · The paper itself

Abstract

GPR119 is a G protein-coupled receptor expressed on enteroendocrine L-cells that synthesize and secrete the incretin hormone glucagon-like peptide-1 (GLP-1). Although GPR119 agonists stimulate L-cell GLP-1 secretion, there is uncertainty concerning whether GLP-1 biosynthesis is under the control of GPR119. Here we report that GPR119 is functionally coupled to increased proglucagon (PG) gene expression that constitutes an essential first step in GLP-1 biosynthesis. Using a mouse L-cell line (GLUTag) that expresses endogenous GPR119, we demonstrate that PG gene promoter activity is stimulated by GPR119 agonist AS1269574. Surprisingly, transfection of GLUTag cells with recombinant human GPR119 (hGPR119) results in a constitutive and apparently ligand-independent increase of PG gene promoter activity and PG mRNA content. These constitutive actions of hGPR119 are mediated by cAMP-dependent protein kinase (PKA) but not cAMP sensor Epac2. Thus, the constitutive action of hGPR119 to stimulate PG gene promoter activity is diminished by: 1) a dominant-negative Gαs protein, 2) a dominant-negative PKA regulatory subunit, and 3) a dominant-negative A-CREB. Interestingly, PG gene promoter activity is stimulated by 6-Bn-cAMP-AM, a cAMP analog that selectively activates α and β isoforms of type II, but not type I PKA regulatory subunits expressed in GLUTag cells. Finally, our analysis reveals that a specific inhibitor of Epac2 activation (ESI-05) fails to block the stimulatory action of 6-Bn-cAMP-AM at the PG gene promoter, nor is PG gene promoter activity stimulated by: 1) a constitutively active Epac2, or 2) cAMP analogs that selectively activate Epac proteins. Such findings are discussed within the context of ongoing controversies concerning the relative contributions of PKA and Epac2 to the control of PG gene expression.

Indexed as

AnimalsCell LineCyclic AMPCyclic AMP-Dependent Protein KinasesEnteroendocrine CellsEthanolaminesGene Expression RegulationGlucagon-Like Peptide 1Guanine Nucleotide Exchange FactorsHEK293 CellsHumansIncretinsL CellsMiceProglucagonPromoter Regions, Genetic2-(2-(4-bromophenyl)-6-methylpyrimidin-4-yl)aminoethanolA-CREB proteinCyclic AMPCyclic AMP-Dependent Protein KinasesEthanolaminesGlucagon-Like Peptide 1GPR119 protein, humanGuanine Nucleotide Exchange FactorsIncretinsProglucagonPyrimidinesRapgef4 protein, mouseReceptors, G-Protein-CoupledRecombinant Fusion ProteinsRNA, Messenger

Identifiers

PMID23798572
PMCPMC3725342
OpenAlexW2046526895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.